The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
Open accessAbstract
The messenger RNA vaccine BNT162b2 (Pfizer–BioNTech) has 95% efficacy against coronavirus disease 2019 (Covid-19). Qatar launched a mass immunization campaign with this vaccine on December 21, 2020. As of March 31, 2021, a total of 385,853 persons had received at least one vaccine dose and 265,410 had completed the two doses. Vaccination scale-up occurred as Qatar was undergoing its second and third waves of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which were triggered by expansion of the B.1.1.7 variant (starting in mid-January 2021) and the B.1.351 variant (starting in mid-February 2021). The B.1.1.7 wave peaked during the first week of March, and the rapid expansion of B.1.351 started in mid-March and continues to the present day. Viral genome sequencing conducted from February 23 through March 18 indicated that 50.0% of cases of Covid-19 in Qatar were caused by B.1.351 and 44.5% were caused by B.1.1.7. Nearly all cases in which virus was sequenced after March 7 were caused by either B.1.351 or B.1.1.7.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Reduced protection against any symptomatic COVID-19 disease caused by the B.1.351 variant of concern (now known as the Beta variant) has been reported from clinical trials18, but emerging data suggest that there remains high protection against the important end points of severe disease and hospitalization99.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [99]
The cited source says what the claim attributes to it.
In the citing paper
“The test-negative design, which does not assume that a lack of a positive test equals a negative test and somewhat adjusts for testing volume, attempts to better mitigate this bias and is the reason we chose this method for this analysis”
From Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine (2022) · cites this paper as [25]
In the citing paper
“These inclusion and exclusion criteria were implemented to allow for build-up of immunity after vaccination4,14 and to minimize different types of potential bias, as informed by earlier analyses in the same population.”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [14]
In the citing paper
“Effectiveness was assessed with the use of an observational, test-negative, case–control design rather than a design in which cohorts of individual persons were followed up. However, the cohort study design applied earlier to the same population yielded findings similar to those of the test-negative design.14,15,31”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [14]
In the citing paper
“However, the cohort study design applied earlier to the same population of Qatar yielded findings similar to those of the test-negative case–control design36,38,39, supporting the validity of this standard approach in assessing vaccine effectiveness11,12,36,40.”
From Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar (2022) · cites this paper as [38]
In the citing paper
“As compared with recent findings from Qatar on the effectiveness of the BNT162b2 vaccine against the alpha and beta variants,17 our findings suggest that effectiveness against the delta variant after a full vaccination course lies somewhere between these two.”
From Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant (2021) · cites this paper as [17]
In the citing paper
“In cohort studies from Israel and Qatar, the BNT162b vaccine also retained greater than 90% efficacy against this variant 210,211 (TABLe 2).”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [211]
In the citing paper
“In the previously cited Qatar cohort study, the efficacy of BNT162b against the Beta variant was estimated to be 72%, which was 15% lower than that for the Alpha variant 211 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [211]
In the citing paper
“Likewise, clinical studies have reported somewhat reduced efficacy and effectiveness against the B.1.1.7, B.1.351, and B.1.617.2 variants (10–12).”
From Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) · cites this paper as [10]
In the citing paper
“The effectiveness of the BNT162b2 vaccine against the Beta variant was measured shortly after the population of Qatar had been vaccinated, whereas the effectiveness of BNT162b2 against the Delta variant was conducted several months after the second dose, which could be one of the reasons for low effectiveness of BNT162b2 against the Delta variant.404,405”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [405]
In the citing paper
“Beta [as a benchmark for partially reduced neutralization (7) without major impact on effectiveness (19, 20)]”
From Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera (2022) · cites this paper as [19]
In the citing paper
“Coronavirus disease 2019 (Covid-19) vaccines are highly effective against symptomatic disease and, more so, against severe disease and fatal outcomes caused by the original strain of SARS-CoV-2 as well as the alpha (B.1.1.7) variant that predominated in early 2021.”
From Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern (2021) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A., Lutrick, K., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7013e3 · Cited by 707
The test-negative design for estimating influenza vaccine effectiveness
Jackson, M. L., & Nelson, J. C. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.02.053 · Cited by 510
Cited by
Sorted by citations
Items 701–800 of 879
SARS-CoV-2 immunity and an overview of the COVID-19 vaccines
Marković, M. (2021) · Medicinski podmladak · doi:10.5937/mp72-33315 · Cited by 3
A Pre-Vaccination Baseline of SARS-CoV-2 Genetic Surveillance and Diversity in the United States
Capoferri, A. A., Shao, W., Spindler, J., Coffin, J. M., Rausch, J. W., & Kearney, M. F. (2022) · Viruses · doi:10.3390/v14010104 · Cited by 3
Moline, H. L., Keaton, A. A., Rice, W., Varghese, J., Deng, L., Waters, A. V., Barringer, A., Winston, D., Fields, V., Slifka, K. J., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac526 · Cited by 3
Side Effects of COVID-19 Vaccines in Patients with Inflammatory Bowel Disease in Japan
Miyazaki, H., Watanabe, D., Ito, Y., Okamoto, N., Tokunaga, E., Ku, Y., Ooi, M., Hoshi, N., & Kodama, Y. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07703-5 · Cited by 3
Timeline of Oxygen Demand in Patients with COVID-19 Pneumonia
Oda, T., Hagiwara, E., Yamaya, T., & Ogura, T. (2022) · Internal Medicine · doi:10.2169/internalmedicine.0190-22 · Cited by 3
Tschiderer, L., Seekircher, L., Richter, L., von Laer, D., Lass‐Flörl, C., Forer, L., Schönherr, S., Krammer, F., Embacher-Aichhorn, S., Tilg, H., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105380 · Cited by 3
Wang, C., Li, Y., Pan, Y., Zhou, L., Zhang, X., Yan, W., Guo, F., Shu, Y., & Gao, J. (2022) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200054 · Cited by 3
Cell-based passive immunization for protection against SARS-CoV-2 infection
Sawula, E., Miersch, S., Jong, E. D., Li, C., Chou, F.-Y., Tang, J. K., Saberianfar, R., Harding, J. S., Sidhu, S. S., & Nagy, A. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03556-5 · Cited by 3
Insights into the evolution of mutations in SARS-CoV-2 non-spike proteins
Arya, R., Tripathi, P., Nayak, K., Ganesh, J., Bihani, S. C., Ghosh, B., Prashar, V., & Kumar, M. (2023) · Microbial Pathogenesis · doi:10.1016/j.micpath.2023.106460 · Cited by 3
Dimitrov, G., Kalinov, K., & Valkov, T. (2023) · American Journal of Infection Control · doi:10.1016/j.ajic.2023.12.015 · Cited by 3
Oh, T. K., Kim, S., Kim, D. H., & Song, I. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202307-607oc · Cited by 3
What is Currently Known About the SARS-CoV2 Variants of Concern
Souaid, T., Hindy, J.-R., & Kanj, S. S. (2021) · Journal of Epidemiology and Global Health · doi:10.2991/jegh.k.210605.001 · Cited by 3
SARS-CoV-2 vaccine effectiveness trumps immunogenicity in solid organ transplant recipients
Mossad, S. B. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16744 · Cited by 3
Proactive COVID-19 testing in a partially vaccinated populationPreprint
McGee, R. S., Homburger, J. R., Williams, H., Bergstrom, C. T., & Zhou, A. Y. (2021) · medRxiv · doi:10.1101/2021.08.15.21262095 · Cited by 3
Optimized Post-Vaccination Strategies and Preventative Measures for SARS-CoV-2Preprint
Pettit, R. W., Peng, B., Yu, P. L., Matos, P. G., Greninger, A. L., McCashin, J., & Amos, C. I. (2021) · medRxiv · doi:10.1101/2021.09.17.21263723 · Cited by 3
Ouarab, M., Bouaiti, E., Rhazzar, Z., Annaz, H. E., Kochri, S. E., Hemlali, M., Ghammaz, H., Nyabi, O., Bakkouri, K. E., Touil, N., et al. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1359 · Cited by 2
SARS-CoV-2 vaccines elicit differential Fc effector functions
Manamela, N. P., Motsoeneng, B. M., Spencer, H., Hermanus, T., Mzindle, N. B., Ayres, F., Makhado, Z., Serage, R., Gray, G., Bekker, L., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113084 · Cited by 4
Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127556 · Cited by 2
Self-citationChemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11410-7 · Cited by 2
Self-citationModeling of antibody responses to COVID-19 vaccination in patients with rheumatoid arthritis
Kim, Y. K., Choi, Y., Jung, J. I., Kim, J. Y., Kim, M. H., Curtis, J. R., & Lee, E. B. (2024) · Scientific Reports · doi:10.1038/s41598-024-51535-4 · Cited by 2
Oberste, M., Asenova, T., Ernst, A., Shah‐Hosseini, K., Schnörch, N., Buess, M., Rosenberger, K. D., Kossow, A., Dewald, F., Neuhann, F., et al. (2024) · BMC Public Health · doi:10.1186/s12889-024-17958-4 · Cited by 2
Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How?
Lippi, G., Henry, B. M., & Plebani, M. (2021) · Diagnostics · doi:10.3390/diagnostics11060941 · Cited by 2
Efficacy and effectiveness of COVID-19 vaccines
Li, Y., & Lu, J. (2021) · One Health Bulletin · doi:10.4103/2773-0344.329027 · Cited by 2
Which vaccination strategy against COVID-19?
Matteis, A. D., Türkmen-Ceylan, F. B., & Urpis, E. (2022) · International Health · doi:10.1093/inthealth/ihac023 · Cited by 2
Chandrasekar, S., Phanse, Y., Riel, M., Hildebrand, R. E., Hanafy, M., Osorio, J. E., Abdelgayed, S. S., & Talaat, A. M. (2022) · Viruses · doi:10.3390/v14061262 · Cited by 2
Kurashima, K., Numano, T., Yoshino, A., Osawa, A., Takaku, Y., Kagiyama, N., & Yanagisawa, T. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.035 · Cited by 2
The continuance intention to vaccinate against COVID-19: An empirical study from Malaysia
Hwang, L.-A., Vaithilingam, S., Ng, J. W. J., Nair, M. S., Ahmed, P. K., & Musa, K. I. (2024) · PLoS ONE · doi:10.1371/journal.pone.0301383 · Cited by 2
de Miranda, É. J. F. P., Calado, R. T., Boulos, F. C., Moreira, J., Machado, F. F., Almeida, M. A. A. L. D. S., Rocha, M. C. O. D., Infante, V., Mercer, L. D., Hjorth, R. N., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2024.126680 · Cited by 2
Correia, J. P., Dantas, M. E. P. L., de Araújo, J. M. G., & Silva, R. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110840 · Cited by 2
Sharmin, E., Majumder, K., & Ahmed, S. F. (2025) · Scientific Reports · doi:10.1038/s41598-025-12690-4 · Cited by 2
The Need for Pre-vaccination Screening
Mohammadi, M., khamseh, A. K. P., & Varpaei, H. A. (2022) · International Journal of Infection · doi:10.5812/iji-119476 · Cited by 2
Durability analysis of the highly effective mRNA-1273 vaccine against COVID-19
Puranik, A., Lenehan, P. J., O’Horo, J. C., Pawlowski, C., Virk, A., Swift, M. D., Kremers, W. K., Venkatakrishnan, A., Challener, D. W., Breeher, L. E., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac058 · Cited by 2
A Review on Variant of Concern (Delta Variant of COVID 19)
Jangam, K. K., Vikhe, D. N., Jadhav, R. S., & Shinde, G. S. (2022) · Asian Journal of Research in Pharmaceutical Sciences · doi:10.52711/2231-5659.2022.00025 · Cited by 2
Osman, K., Mundodan, J. M., Chowdhury, J., Ravi, R. P., Baaboura, R., Albuquerque, J., Riaz, B., Emran, R. Y., Batoul, K., Esameldin, A. M., et al. (2023) · Vaccines · doi:10.3390/vaccines11101522 · Cited by 2
Assessment of the feasibility of pool testing for SARS-CoV-2 infection screening
Paganini, I., Sani, C., Chilleri, C., Baccini, M., Antonelli, A., Bisanzi, S., Burroni, E., Cellai, F., Coppi, M., Mealli, F., et al. (2022) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2022.2044512 · Cited by 2
Patterns of compliance with COVID-19 preventive measures among the public in Qatar and Kuwait
Lari, N. A., & Al-Thani, N. (2022) · Global Social Policy · doi:10.1177/14680181221092682 · Cited by 2
Coyle, P. V., Kahlout, R. A. E., Dargham, S. R., Chemaitelly, H. S., Kacem, M. A. B. H., Al-Mawlawi, N., Gilliani, I., Younes, N., Kanaani, Z. A., Al‐Khal, A., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262897 · Cited by 2
Self-citationImmune System Diversity Against SARS-CoV-2 Infection and Vaccines
Mortaz, E., & Adcock, I. M. (2022) · Journal of Preventive Diagnostic and Treatment Strategies in Medicine · doi:10.4103/jpdtsm.jpdtsm_42_22 · Cited by 2
Zhao, D., Wang, X., Liu, J., Chinnappa, A. U., Basavaraj, V., Sri, C. D., Nikolenko, V. N., Beeraka, N. M., Shivaprakash, P., & Fan, R. (2023) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201024666230227115329 · Cited by 2
Arora, R., Sen, K. K., Mitra, A., Dubey, R., Goyal, M., & Sethi, H. S. (2022) · Indian Journal of Respiratory Care · doi:10.4103/ijrc.ijrc_148_21 · Cited by 2
Knabl, L., Lee, H., Wieser, M., Mur, A., Zabernigg, A. F., Knabl, L., Rauch, S., Böck, M., Schumacher, J., Kaiser, N., et al. (2021) · medRxiv · doi:10.1101/2021.05.11.21256862 · Cited by 2
Wu, Y., Xu, S., Yau, S., & Wu, Y. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2111.01969 · Cited by 2
Wu, Y., Xu, S., Yau, S., & Wu, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-1578020/v1 · Cited by 2
Modified or Unmodified mRNA Vaccines? – The Biochemistry of Pseudouridine and mRNA Pseudouridylation
Morais, P., & Yu, Y. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch3 · Cited by 2
Jansen, K. U. (2021) · doi:10.33442/vt202107 · Cited by 1
Frequency of SARS-CoV-2 variants identified by real-time PCR in the AUNA healthcare network, Peru
Ortiz-Gómez, T., Gómez, A. C., Chuima, B., Zevallos, A., Ocampo, K., Torres, D., & Pinto, J. A. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1244662 · Cited by 1
Corte, P. Q., Cano, J., Ayra, E. S., Joshi, C., & Comendador, V. F. G. (2024) · Mathematics · doi:10.3390/math12081241 · Cited by 1
Zhou, P., Watt, J., Mai, J., Cao, H., Li, Z., Chen, Z., Duan, R. C., Quan, Y., Gingras, A., Rini, J. M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1430928 · Cited by 1
Brown, J. P., Mook, P., Vanhaverbeke, M., Gimma, A., Hagan, J. E., Singini, I. L., Avdičová, M., Cullen, G., Dotsenko, L., Mossong, J., et al. (2025) · Epidemiology and Infection · doi:10.1017/s0950268824001833 · Cited by 1
Amona, E. B., Sahoo, I., Boone, E. L., & Ghanam, R. (2025) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph22050731 · Cited by 1
ACE2 Receptor and Antibody Binding to SARS-CoV-2 Spikes and Virions by Single-Molecule Fluorescence
Dasgupta, S., Ray, S., Srivatsav, A. T., DeVico, A. L., & Ray, K. (2025) · ACS Omega · doi:10.1021/acsomega.5c03887 · Cited by 1
Retrospective neutralization analysis of SARS-CoV-2 variants in early pandemic sera
Mahdi, M., Al-Muffti, A. S., Linkner, T. R., Miltner, N., Misak, O., Várkonyi, I. Z., & Tőzsér, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1797240 · Cited by 1
Healthy vaccinee effect did not bias COVID-19 vaccine effectiveness estimates
Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2026) · Communications Health · doi:10.1038/s44528-026-00006-5 · Cited by 1
Self-citationZhou, L., Hsieh, C., Leist, S. R., Miller, E. H., Horton, A. P., Shoemaker, S. R., Gardner, E. C., Powers, J. M., Boutz, D. R., Mallory, M. L., et al. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1014391 · Cited by 1
La nécessité d’une surveillance génomique liée du SRAS-CoV-2
Colijn, C., Earn, D. J. D., Dushoff, J. G., Ogden, N. H., Li, M., Knox, N., Domselaar, G. V., Franklin, K., Jolly, G., & Otto, S. P. (2022) · Relevé des maladies transmissibles au Canada · doi:10.14745/ccdr.v48i04a03f · Cited by 1
Jacobs, M. M., Karp, A., Alessandro, C., Ganz, M., Glatt, A. E., Rosenberg, A. Z., Wang, R., Zimmerman, J., Silverberg, J. I., & Zyskind, I. (2022) · Cureus · doi:10.7759/cureus.33190 · Cited by 1
Klessing, S., Peter, A. S., Fraedrich, K., Wagner, J. T., Kummer, M., Deutschmann, J., Steininger, P. A., Steibl, H.-D., & Überla, K. (2023) · Viruses · doi:10.3390/v15020397 · Cited by 2
Bahar, N. F., Usman, M., Kahar, A., & Hermansyah, S. (2023) · Journal International Inspire Education Technology · doi:10.55849/jiiet.v2i3.448 · Cited by 1
Wondal, R., Mahmud, N., Arfa, U., Oktaviani, W., & Djaenal, N. A. (2023) · Journal International Inspire Education Technology · doi:10.55849/jiiet.v2i3.469 · Cited by 1
Albogami, Y., Alalwan, A., Batais, M. A., Alabdulkareem, K. I., & Alalwan, A. A. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.09.014 · Cited by 1
Sinnathamby, M., Zaidi, A., Twohig, K. A., Aliabadi, S., Aziz, N. I. B. A., Groves, N., Gallagher, E., Thelwall, S., & Dabrera, G. (2023) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13204 · Cited by 1
Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0331654 · Cited by 1
Self-citationJafar, A. J. N., Darbyshire, D., Prager, G., Reynard, C., & Naguib, M. P. (2020) · Emergency Medicine Journal · doi:10.1136/emermed-2020-210979 · Cited by 1
COVID flood, can vaccines withstand?
Elghannam, R., & Abo-Elmagd, M. (2021) · Medicine Updates · doi:10.21608/muj.2021.94130.1058 · Cited by 1
Al, L. İ. R., Sönmezer, M. Ç., & Ünal, S. (2021) · Flora the Journal of Infectious Diseases and Clinical Microbiology · doi:10.5578/flora.20219703 · Cited by 1
A practical approach to SARS-CoV-2 testing in a pre and post-vaccination era
Taylor, S. C. (2021) · Journal of Clinical Virology Plus · doi:10.1016/j.jcvp.2021.100044 · Cited by 1
Global Biologic Characteristics of Variants of Concern and Variants of Interest of SARS-CoV-2
Singh, J., Ehtesham, N. Z., Hira, S., Shrestha, U. K., & Hasnain, S. E. (2022) · Springer eBooks · doi:10.1007/978-3-031-08045-6_8 · Cited by 1
Chaudhary, S., El‐Shorbagi, A., Chaudhary, A., Agarwal, G., Tripathi, P. N., & Dumoga, S. (2022) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2456 · Cited by 1
Kumar, A., Sharma, A., Tirpude, N. V., Padwad, Y. S., Sharma, S., & Kumar, S. (2022) · Infectious diseases · doi:10.5772/intechopen.107844 · Cited by 1
Durability of antibodies post vaccination with two doses of inactivated BBIBP-CorV vaccine
Mahmoud, S., Ganesan, S., Sharif‐Askari, N. S., Cantarutti, F. M., Wilson, H. V., Ogrodzki, P., Halwani, R., Kaabi, N. A., & Zaher, W. A. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2139969 · Cited by 1
A genetically engineered, stem-cell-derived cellular vaccine
Cooper, A., Sidaway, A., Chandrashekar, A., Latta, E., Chakraborty, K., Yu, J., McMahan, K., Giffin, V. M., Manickam, C., Kroll, K. W., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100843 · Cited by 1
Optimized workplace risk mitigation measures for SARS-CoV-2 in 2022
Pettit, R. W., Peng, B., Yu, P. L., Matos, P. G., Greninger, A. L., McCashin, J., & Amos, C. I. (2023) · Scientific Reports · doi:10.1038/s41598-023-29087-w · Cited by 1
Taghioff, S. M., Slavin, B. R., Mehra, S., Holton, T., & Singh, D. P. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281990 · Cited by 1
Vaccine effectiveness against the B.1.617.2 in the intensive care unit
Koc, I., Ozmen, S. U., & Deniz, O. (2023) · Medicine · doi:10.1097/md.0000000000035588 · Cited by 1
Curriculum Evaluation of Study Program of Christian Religious Colleges
Oci, M., Roesmijati, R., Telaumbanua, A., Haniko, P., & Pane, R. T. H. (2024) · Journal International Inspire Education Technology · doi:10.55849/jiiet.v3i1.525 · Cited by 1
Joffe, A. R., & Redman, D. (2021) · Preprints.org · doi:10.20944/preprints202105.0264.v1 · Cited by 1
Miller, N. L., Clark, T., Raman, R., & Sasisekharan, R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.07.446560 · Cited by 1
Effectiveness of the SARS-CoV-2 mRNA Vaccines in Pregnant WomenPreprint
Butt, A. A., Abou‐Samra, A., Chemaitelly, H. S., Al‐Khal, A., Coyle, P. V., Saleh, H., Kaleeckal, A. H., Latif, A. N., Bertollini, R., & Abu-Raddad, L. J. (2021) · Research Square · doi:10.21203/rs.3.rs-622782/v1 · Cited by 1
Self-citationDe-Leon, H., & Pederiva, F. (2021) · medRxiv · doi:10.1101/2021.08.10.21261856 · Cited by 1
MITIGATING THE 4 th WAVE OF THE COVID-19 PANDEMIC IN ONTARIOPreprint
Cipriano, L. E., Haddara, W. M. R., & Sander, B. (2021) · medRxiv · doi:10.1101/2021.09.02.21263000 · Cited by 1
Mahajan, A., Sivadas, N., & Panda, P. (2022) · doi:10.36227/techrxiv.17705957.v1 · Cited by 1
Paul, E., & Fancourt, D. E. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3989842 · Cited by 1
COVID-19 Rapid Guideline - Organisation and Management in Low Resource Countries
Vancheeswaran, R., Barlow, A., Pyae, P. K., O'Neill, A., Vancheeswaran, V., Mitchell, H., Cama, R., & der Watt, M. V. (2021) · The Physician · doi:10.38192/1.7.1.7
Kudaiberdieva, G. (2021) · Heart Vessels and Transplantation · doi:10.24969/hvt.2021.253
The new context in which breakthrough infections might emerge
Jolobe, O. M. P. (2021) · QJM · doi:10.1093/qjmed/hcab182
Wilhelm, M. (2021) · Pharmacy Today · doi:10.1016/j.ptdy.2021.07.022
Nikhra, V. (2021) · Journal of Pulmonology and Respiratory Research · doi:10.29328/journal.jprr.1001030
Huang, A., Hu, J., & Zhang, H. (2021) · Infectious Diseases & Immunity · doi:10.1097/id9.0000000000000018
Population Impact of SARS-CoV-2 Variants with Enhanced Transmissibility and/or Partial Immune EscapePreprint
Bushman, M., Kahn, R. J., Taylor, B. P., Lipsitch, M., & Hanage, W. P. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3924614
Lanata, C. F., Ecker, L., Cornejo, R., Celis, C. R., Díaz-Parra, C. D. P., de León, S. A. R. P., Flores, O., Ochoa, M., Peña, B., & Gil, A. I. (2021) · Diagnóstico · doi:10.33734/diagnostico.v60i3.305
Vijayalakshmi, S., Manivannane, K., & Malarvizhi, N. (2021) · Shanlax International Journal of Arts Science and Humanities · doi:10.34293/sijash.v9i2.4384
Infectiologie : vaccins contre la COVID-19
Aupiais, C. (2021) · Perfectionnement en Pédiatrie · doi:10.1016/s2588-932x(21)00197-2
An Overview of the COVID-19 Vaccine Effectiveness
Al‐Jumaili, A. A., & Younus, M. M. (2021) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v1i.38
Biomedical advances in the treatment of COVID-19
Iyer, R. K., Venkataramanan, V., Pierce, G. N., Thakkar, N., Natarajan, V., & Chockalingam, A. (2021) · International Journal of Noncommunicable Diseases · doi:10.4103/2468-8827.330647
Jaffal, K., & Mascitti, H. (2021) · Infectious Diseases Now · doi:10.1016/s2666-9919(21)00555-8
COVID‐19 Vaccine Efficacy and the Evidence on BoostersPreprint
Black, B. S., & Thaw, D. B. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3987991
Antigenic Map of SARS-CoV-2 Variants Including OmicronPreprint
Furuse, Y. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3995729
Callanan, R., Deasy, C., Slowey, J., Brien, R. O., Dunphy, M., Dasari, K., Brennan, T., Walsh, S., Gilmartin, S., Sullivan, I. O., et al. (2021) · Emergency Medicine Journal · doi:10.1136/emermed-2021-211704
The Impact of COVID-19 on Hospitality Travelers’ Safety and the Quality of LifePreprint
Feniza, A. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.4016146
The Role of Artificial Intelligence and Data Science Against COVID-19
Tripathi, S., & Sharma, D. K. (2022) · Lecture notes in electrical engineering · doi:10.1007/978-981-19-0284-0_10
Metadata
- Authors
- Abu-Raddad, L. J., Chemaitelly, H., & Butt, A. A.
- Affiliations
- Weill Cornell Medical College in Qatar (QA)
- Hamad Medical Corporation (QA)
- Corresponding author
- Abu-Raddad, Laith J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-07-08
- Volume
- 385
- Issue
- 2
- Pages
- 187-189
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8117967
- OpenAlex
- W3157162195
- Cited by
- 899
- References
- 4
- Citations by year
- 2026: 16 · 2025: 32 · 2024: 46 · 2023: 92 · 2022: 358 · 2021: 351
- FWCI
- 67.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Qatar University QSpace (Qatar University) (submittedVersion)
- Funders
- Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, the Ministry of Public Health and Hamad Medical Corporation
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- BNT162b2, COVID-19 vaccine efficacy, SARS-CoV-2 variants, B.1.1.7 variant, B.1.351 variant, Omicron variant, vaccination campaigns, viral genome sequencing, COVID-19 waves
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Humans, Qatar, Cohort Studies, Case-Control Studies, Polymerase Chain Reaction, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
